Eculizumab versus rituximab in generalised myasthenia gravis. Issue 5 (4th March 2022)

• Record Type: Journal Article
• Authors: Nelke, Christopher; Schroeter, Christina B; Stascheit, Frauke; Pawlitzki, Marc; Regner-Nelke, Liesa; Huntemann, Niklas; Arat, Ercan; Öztürk, Menekse; Melzer, Nico; Mergenthaler, Philipp; Gassa, Asmae; Stetefeld, Henning; Schroeter, Michael; Berger, Benjamin; Totzeck, Andreas; Hagenacker, Tim; Schreiber, Stefanie; Vielhaber, Stefan; Hartung, Hans-Peter; Meisel, Andreas; Wiendl, Heinz; Meuth, Sven G; Ruck, Tobias
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 93:Issue 5(2022)
• Page Start: 548
• Page End: 554
• Publication Date: 2022-03-04
• Subjects: myasthenia -- neuromuscular -- neuroimmunology; Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2021-328665
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Objective: Myasthenia gravis (MG) is the most common autoimmune disorder affecting the neuromuscular junction. However, evidence shaping treatment decisions, particularly for treatment-refractory cases, is sparse. Both rituximab and eculizumab may be considered as therapeutic options for refractory MG after insufficient symptom control by standard immunosuppressive therapies. Methods: In this retrospective observational study, we included 57 rituximab-treated and 20 eculizumab-treated patients with MG to compare the efficacy of treatment agents in generalised, therapy-refractory anti-acetylcholine receptor antibody (anti-AChR-ab)-mediated MG with an observation period of 24 months. Change in the quantitative myasthenia gravis (QMG) score was defined as the primary outcome parameter. Differences between groups were determined in an optimal full propensity score matching model. Results: Both groups were comparable in terms of clinical and demographic characteristics. Eculizumab was associated with a better outcome compared with rituximab, as measured by the change of the QMG score at 12 and 24 months of treatment. Minimal manifestation of disease was more frequently achieved in eculizumab-treated patients than rituximab-treated patients at 12 and 24 months after baseline. However, the risk of myasthenic crisis (MC) was not ameliorated in either group. Interpretation: This retrospective, observational study provides the first real-world evidence supporting the use of eculizumab for the treatment of refractory, anti-AChR-ab positive MG. Nonetheless, the risk of MC remained high and prompts the need for intensified monitoring and further research effort aimed at this vulnerable patient cohort.